BERMUDA-BUSINESS-DEVELOP
11.5.2023 20:34:29 CEST | Business Wire | Press release
Bermuda’s Deputy Premier, The Hon. Walter Roban, JP, MP will kick off the second annual Bermuda Climate Summit, presented by the Bermuda Business Development Agency (BDA), in partnership with KBRA on June 26.
The Deputy Premier will discuss Bermuda’s key attributes as the world’s climate risk finance capital in a keynote seaside chat with Mark Baker, President & CEO, KBRA.
Deputy Premier Roban said, “I look forward to once again participating in the Bermuda Climate Summit in order to highlight Bermuda’s strengths in climate risk finance, including our strong regulatory environment, long-history of environmental stewardship and wealth of financial services experience.”
The keynote address will be given by Joshua Rosenberg, Chief Risk Officer, Federal Reserve Bank of New York.
Other sessions confirmed to date include: The Power of Partnerships, which will be moderated by Jeff Manson, SVP Underwriting and Head of Global Public Sector Partnership, Renaissance Re Ltd, and will include panellists, Ekhosuehi Iyahen, Secretary General, Insurance Development Forum, Sid Miller, Director, Climate Wise, Rebekah Clement, Head of Sustainability, Lloyds, and Chair of SMI Climate Action Committee, and Tim Nielander, Founder and President, GP3 Institute.
Impact of a Changing Climate on Atlantic Hurricane Frequency and Severity will be moderated by Marla Pourrabbani, Data Scientist, Senior Manager, ESG and Sustainability, Deloitte, and features panellists, Dr. Pete Dailey, Head of Research, Aeolus, Liz Henderson, Co-Head Catastrophe Analytics, Executive Managing Director, Reinsurance Solutions, Aon, Dr. Peter Sousounis, Vice President/Director Climate Change Research, Verisk, Craig Tillman, President, RenaissanceRe Risk Sciences.
Net Zero? will be moderated by Miqdaad Versi, Head of ESG, Oxbow Partners, UK, and feature panellists Rachael Dalheise. Head of Sustainability, Convex, Andrew MacFarlane, Head of Climate, AXA XL, a Division of AXA, and Andrew Smith, Chief Risk and Sustainability Officer at Conduit Re.
Global Climate Risk will include Dr. Mark Guishard, former Director, Bermuda Weather Service, Dr. Raveem Ismail, Head of Parametric Underwriting, Africa Specialty Risks (ASR Re) and Dr. Simon Young, Senior Director, Willis Towers Watson.
What’s Ahead in the United States? will be moderated by John Huff, President & CEO, Association of Bermuda Insurers and Reinsurers (ABIR) and include panellists, Ricardo Lara, Insurance Commissioner, California Department of Insurance and Lori Wing-Heier, Director, Alaska Division of Insurance, and National Association of Insurance Commissioners (NAIC) Representative, Sustainable Insurance Forum.
Chlora Lindley-Myers, NAIC President and Director of the Missouri Department of Commerce and Insurance will speak on a panel entitled The U.S. Federal Flood Programme and the (Re)Insurance Sector, moderated by Peter Giacone, Global Head of Insurance, KBRA and including fellow panellists, Chris Brown – Partner, Mindset and Andy Neal, Managing Director, Public Private Partnerships, Aon.
David Hart, BDA, CEO said, “The theme of this year’s event is ‘Bermuda - Climate Central’ and we are honoured to have Deputy Premier Roban join us to open the 2023 Bermuda Climate Summit. We are equally pleased to have so many leading climate experts across different fields coming to Bermuda to engage with our audience on why climate is such an important topic. We also look forward to meeting with potential overseas investors to share why Bermuda is the perfect place to develop climate risk finance solutions.”
Click here to register for this important event. Overseas guests are also reminded to book their hotel rooms online before May 25, to enjoy special rates at our event hotel, the Hamilton Princess & Beach Club.
The BDA is grateful for the continued support of our headline sponsor KBRA, as well as: diamond sponsor Conduit Re; platinum sponsor Aon, gold sponsors Deloitte, Fidelis and Hub Culture; and silver sponsors Aeolus, Aspen, AXA XL, Belco, and KPMG. Our supporting sponsors are Butterfield and HSBC. Our media partners are The Insurer, Insurance Insider and Bermuda:Re+ILS. Goslings is our spirits partner. Other sponsorship opportunities are still available; please e-mail bermudaclimate@bda.bm if you wish to participate.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005841/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom